All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Study Shows Real-World Benefit of Rituximab Maintenance After Frontline BR in Mantle Cell Lymphoma

July 23rd 2024

Rituximab maintenance therapy following frontline bendamustine plus rituximab improved EFS, EFS2, and OS vs no maintenance therapy in patients with MCL.

Landmark Study Shows Elevated Cancer Risk For Women With Endometriosis

July 23rd 2024

Women with severe endometriosis are 10 times more likely to get ovarian cancer, compared to women who do not have the disease.

Iopofosine I 131 Meets MRR End Point in R/R Waldenström Macroglobulinemia

July 23rd 2024

Iopofosine I 131 generated a major response rate of 56.4% in patients with relapsed/refractory Waldenström macroglobulinemia.

FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

July 23rd 2024

The FDA has accepted the resubmission of a BLA for remestemcel-L in pediatric steroid-refractory acute graft-vs-host-disease.

FDA Grants Fast Track Designation to Ozuriftamab Vedotin in Recurrent/Metastatic HNSCC

July 23rd 2024

The ROR2-targeted ADC ozuriftamab vedotin has received FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

Perioperative PD-1 Inhibition Expands Treatment Opportunities for Select Patients With CSCC

July 23rd 2024

Vishal Patel, MD, FAAD, FACMS, highlights the evolving role of PD-1 inhibitors in the management of nonmelanoma skin cancers.

DESTINY-Breast03 and DESTINY-Breast06 Data Shape Metastatic Breast Cancer Treatment

July 23rd 2024

Paolo Tarantino MD, and V. K. Gadi, MD, PhD discuss data from DESTINY-Breast03 and DESTINY-Breast06.

Neoadjuvant Therapy Selection: Are Abbreviated Regimens an Option in HER2+ Breast Cancer?

July 23rd 2024

Adrienne G. Waks, MD, parses out recent and upcoming data in HER2+ breast cancer and discusses why abbreviated neoadjuvant regimens are not ready for primetime.

Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer

July 22nd 2024

Sonya Reid, MD, MPH, discusses barriers to universal germline testing utilization in breast cancer, particularly among underserved populations.

Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium

July 22nd 2024

Sarah Sammons, MD, discusses the evolving treatment landscape for metastatic HER2-postive breast cancer.

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management

July 22nd 2024

Circulating tumor DNA is in constant flux, rendering its evaluation potentially useful in metastatic breast cancer management.

V. Craig Jordan, PhD, the ‘Father of Tamoxifen,’ Dies at 76

July 22nd 2024

V. Craig Jordan, PhD, of The University of Texas MD Anderson Cancer Center and a pioneer in the field of breast cancer, died on June 9, 2024.

Five-Year Follow-Up Data Confirm Long-Term Benefits of Olutasidenib in R/R IDH1+ AML

July 22nd 2024

Justin M. Watts, MD, discusses 5-year efficacy and safety data for olutasidenib in IDH1-mutant, relapsed/refractory AML.

Pembrolizumab Plus B-Cell Receptor Inhibitors Generates Responses in Richter Transformation of CLL/SLL

July 22nd 2024

Pembrolizumab plus ibrutinib or idelalisib produced responses in patients with Richter transformation of chronic lymphocytic leukemia.

FDA Grants Fast Track Designation to HP518 for AR+ TNBC

July 22nd 2024

The FDA has granted fast track designation to HP518 for androgen receptor–positive triple-negative breast cancer.

FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park

July 22nd 2024

The FDA has expanded the orphan drug designation for SurVaxM, a brain cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center.

340B Drug Pricing Program Ostensibly Improves Cancer Care but Carries Unforeseen Consequences

July 22nd 2024

Kassem Faraj, MD, details the 340B Drug Pricing program and data from a study examining participation in the program for patients with advanced prostate cancer.

KIM-1 Demonstrates Potential Utility as a Biomarker With Worse DFS Outcomes in KIM-1–High RCC

July 21st 2024

Brian Rini, MD, details recent data in renal cell carcinoma surrounding the utility of KIM-1 as a potential biomarker and next steps for KIM-1 research.

De-Escalation Strategies, Biomarkers Could Refine Treatment Algorithm for Early-Stage HER2+ Breast Cancer

July 20th 2024

Sara M. Tolaney, MD, MPH, discusses the use of HER2-directed therapy in the curative setting for HER2-positive breast cancer.

Roswell Park Appoints 5 New Leaders Overseeing Key Areas of Patient Care and Support

July 20th 2024

Roswell Park Comprehensive Cancer Center has promoted 3 nurses to leadership roles and new leaders were named in Case Management and Patient Education.